CUE-induced drug craving monitoring for opioid use disorder with visual evoked potentials
Active Project Grant Awarded Last action
- Award ID
- R44DA059517
- Recipient
-
Neurotype Inc. UEI CKJEWEVBWP54
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,528,271
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 55% complete
- Originally
- Place of performance
- Minneapolis, MN 55406, USA
Award details come from USAspending.gov.
Description
- Abstract
- More than 2 million people in the united states have an opioid use disorder (OUD). Overall, at least half of the treatment-seeking population relapse, contributing to over 75,000 overdose deaths annually. The purpose of this sbir fast-track application is to create a regulated device to objectively monitor CUE-induced craving (CIC) in opioid use disorder (OUD) patients. CIC, which is caused by environmental triggers, is a major factor in OUD drug use and relapse but currently, there are no standard tools to measure IT. The neuromarkr™ software interfaces with electroencephalogram (EEG) systems to quantify the extent to which event-related potential (ERP) brain responses elicited by opioid cues (e.g., image containing a pill bottle) resemble brain responses elicited by naturally appetitive cues (e.g., palatable foods). The phase i specific aims include integrating neuromarkr™ with a highly portable and usable EEG system that is already cleared by the food and drug administration (FDA), and conducting clinical usability and bench testing. The phase II specific aims include evaluating a CIC neuro-affective profile (CIC-NAP) with respect to opioid craving and other OUD outcomes through clinical trials. Of central focus, the CIC-NAP biomarker will be evaluated by its prediction of clinical outcomes such as recent and prospective drug use, among other variables. The safety and efficacy results will be included in an anticipated class II DE novo request that will be submitted to the FDA.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $870,345 | |
| Amendment | -$0 | |
| Amendment | -$0 | |
| Amendment | $0 | |
| Amendment | $328,963 | |
| Original award | $328,963 |
Quick answers
Who received award R44DA059517?
R44DA059517 was awarded to Neurotype Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2023.
How much is award R44DA059517 worth?
$1,528,271 has been obligated on R44DA059517.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award